Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 20/20 | 0.67 |
| ▸ | AVPR1B | P47901 | 10/20 | 0.64 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656330 | 0.98 | OXTR (0.63) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651017 | 0.97 | OXTR (0.68) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651023 | 0.97 | OXTR (0.66) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651020 | 0.96 | OXTR (0.69) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651034 | 0.95 | OXTR (0.66) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL17323310 | 0.94 | OXTR (0.65) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL17323284 | 0.94 | OXTR (0.73) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651037 | 0.93 | OXTR (0.66) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18656366 | 0.92 | OXTR (0.62) | OXTRAVPR1BAVPR2AVPR1A | |
| SCHEMBL18651030 | 0.92 | OXTR (0.64) | OXTRAVPR1BAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957298-B2 | Peptides as oxytocin agonists | HOFFMANN-LA ROCHE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957298-B2 | Peptides as oxytocin agonists | HOFFMANN-LA ROCHE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170081369-A1 | PEPTIDES AS OXYTOCIN AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081369-A1 | PEPTIDES AS OXYTOCIN AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2017-03-23 | — | — | US | disclosed |
| WO-2015185467-A1 | PEPTIDES AS OXYTOCIN AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081369-A1 | PEPTIDES AS OXYTOCIN AGONISTS | OXTR, AVPR1B, AVPR1A | OXTR 1/4885AVPR1B 2/4885AVPR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.